336 related articles for article (PubMed ID: 32634355)
1. Lessons From The Impact Of Price Regulation On The Pricing Of Anticancer Drugs In Germany.
Lauenroth VD; Kesselheim AS; Sarpatwari A; Stern AD
Health Aff (Millwood); 2020 Jul; 39(7):1185-1193. PubMed ID: 32634355
[TBL] [Abstract][Full Text] [Related]
2. Analysis of Launch and Postapproval Cancer Drug Pricing, Clinical Benefit, and Policy Implications in the US and Europe.
Vokinger KN; Hwang TJ; Daniore P; Lee CC; Tibau A; Grischott T; Rosemann TJ; Kesselheim AS
JAMA Oncol; 2021 Sep; 7(9):e212026. PubMed ID: 34196656
[TBL] [Abstract][Full Text] [Related]
3. Increasing Divergence in Drug Prices Between the United States and Germany After Implementation of Comparative Effectiveness Analysis and Collective Price Negotiations.
Berkemeier F; Whaley C; Robinson JC
J Manag Care Spec Pharm; 2019 Dec; 25(12):1310-1317. PubMed ID: 31778624
[TBL] [Abstract][Full Text] [Related]
4. Why France Spends Less Than the United States on Drugs: A Comparative Study of Drug Pricing and Pricing Regulation.
Raimond VC; Feldman WB; Rome BN; Kesselheim AS
Milbank Q; 2021 Mar; 99(1):240-272. PubMed ID: 33751664
[TBL] [Abstract][Full Text] [Related]
5. Price negotiation and pricing of anticancer drugs in China: An observational study.
Zhou J; Lan T; Lu H; Pan J
PLoS Med; 2024 Jan; 21(1):e1004332. PubMed ID: 38166148
[TBL] [Abstract][Full Text] [Related]
6. Price changes and within-class competition of cancer drugs in the USA and Europe: a comparative analysis.
Vokinger KN; Hwang TJ; Carl DL; Laube Y; Ludwig WD; Naci H; Kesselheim AS
Lancet Oncol; 2022 Apr; 23(4):514-520. PubMed ID: 35271804
[TBL] [Abstract][Full Text] [Related]
7. Pharmaceutical Pricing in Germany: How Is Value Determined within the Scope of AMNOG?
Lauenroth VD; Stargardt T
Value Health; 2017; 20(7):927-935. PubMed ID: 28712622
[TBL] [Abstract][Full Text] [Related]
8. Structural changes in the German pharmaceutical market: price setting mechanisms based on the early benefit evaluation.
Henschke C; Sundmacher L; Busse R
Health Policy; 2013 Mar; 109(3):263-9. PubMed ID: 23339876
[TBL] [Abstract][Full Text] [Related]
9. German Pharmaceutical Pricing: Lessons for the United States.
Rodwin MA; Gerke S
Int J Health Serv; 2022 Jan; 52(1):146-158. PubMed ID: 34668806
[TBL] [Abstract][Full Text] [Related]
10. 10 Years of AMNOG: What is the Willingness-to-Pay for Pharmaceuticals in Germany?
Büssgen M; Stargardt T
Appl Health Econ Health Policy; 2023 Sep; 21(5):751-759. PubMed ID: 37249741
[TBL] [Abstract][Full Text] [Related]
11. The High Cost of Prescription Drugs in the United States: Origins and Prospects for Reform.
Kesselheim AS; Avorn J; Sarpatwari A
JAMA; 2016 Aug 23-30; 316(8):858-71. PubMed ID: 27552619
[TBL] [Abstract][Full Text] [Related]
12. International Reference Pricing for Prescription Drugs in the United States: Administrative Limitations and Collateral Effects.
Rand LZ; Kesselheim AS
Value Health; 2021 Apr; 24(4):473-476. PubMed ID: 33840424
[TBL] [Abstract][Full Text] [Related]
13. [Benefit Assessment and Price Negotiation Under AMNOG: Calculable Process or Unfair Poker Game?].
Radic D; Haugk S; Radic M
Gesundheitswesen; 2018 Jun; 80(6):573-579. PubMed ID: 27636366
[TBL] [Abstract][Full Text] [Related]
14. Reference Pricing in Germany: Implications for U.S. Pharmaceutical Purchasing.
Robinson JC; Panteli D; Ex P
Issue Brief (Commonw Fund); 2019 Feb; 2019():1-8. PubMed ID: 30883061
[TBL] [Abstract][Full Text] [Related]
15. Competitive pricing within pharmaceutical classes: evidence on "follow-on" drugs in Germany 1993-2008.
Mueller MT; Frenzel A
Eur J Health Econ; 2015 Jan; 16(1):73-82. PubMed ID: 24370790
[TBL] [Abstract][Full Text] [Related]
16. Prices and Clinical Benefit of National Price-Negotiated Anticancer Medicines in China.
Zhang Y; Wei Y; Li H; Chen Y; Guo Y; Han S; Shi L; Guan X
Pharmacoeconomics; 2022 Jul; 40(7):715-724. PubMed ID: 35764914
[TBL] [Abstract][Full Text] [Related]
17. Promoting Access to Innovative Anticancer Medicines: A Review of Drug Price and National Reimbursement Negotiation in China.
Mingge X; Jingyu W; Qi L; Zhe Z; Qing R
Inquiry; 2023; 60():469580231170729. PubMed ID: 37171066
[TBL] [Abstract][Full Text] [Related]
18. Ten years of German benefit assessment: price analysis for drugs with unproven additional benefit.
Kleining K; Laufenberg J; Thrun P; Ehlert D; Wasem J; Bartol A
Health Econ Policy Law; 2023 Aug; ():1-18. PubMed ID: 37577932
[TBL] [Abstract][Full Text] [Related]
19. Medicare Drug Price Negotiation in the United States: Implications and Unanswered Questions.
Sullivan SD
Value Health; 2023 Mar; 26(3):394-399. PubMed ID: 36503034
[TBL] [Abstract][Full Text] [Related]
20. Estimates of Medicaid and Non-Medicaid Net Prices of Top-Selling Brand-name Drugs Incorporating Best Price Rebates, 2015 to 2019.
Clemans-Cope L; Epstein M; Banthin J; Kesselheim AS; Hwang TJ
JAMA Health Forum; 2023 Jan; 4(1):e225012. PubMed ID: 36637815
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]